STAAR Surgical Company - 10-K Filing Summary
Business Context and Reporting Period
Company: STAAR Surgical Company
Filing Type: Form 10-K (Annual Report)
Period Ended: January 3, 2003
Business Overview: STAAR Surgical is a developer, manufacturer, and global distributor of ophthalmic products for cataract, glaucoma, and refractive surgery. While the company operates in three segments, the cataract segment accounted for approximately 95% of revenues in 2002, leading to reporting as a single business segment. Key products include foldable Intraocular Lenses (IOLs), the Implantable Contact Lens (ICL), and the AquaFlow Glaucoma Drainage Device.
Key Financial Metrics (Fiscal Year 2002)
| Metric | 2002 (in thousands) | 2001 (in thousands) |
|---|---|---|
| Total Revenues | $48,248 | $50,786 |
| Gross Profit | $24,149 | $22,583 |
| Gross Margin | 50.1% | 44.5% |
| Operating Loss | $(7,113) | $(17,786) |
| Net Loss | $(17,158) | $(14,833) |
| Loss Per Share (Basic/Diluted) | $(1.00) | $(0.87) |
| Working Capital | $6,792 | $16,780 |
| Cash and Cash Equivalents | $1,009 | $853 |
| Total Debt (Notes Payable) | $5,845 | $8,216 |
Cash Flow: Net cash provided by operating activities was $0.6 million in 2002, compared to a use of $2.5 million in 2001. This improvement was driven by decreases in working capital (accounts receivable and inventory) despite the net loss.
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased 5% ($2.5 million) to $48.2 million. This was primarily due to a 14% decline in U.S. IOL sales (driven by lower unit volume and average selling price). This was partially offset by an 11% increase in international distributed product sales and a 33% increase in ICL sales.
- Margin Improvement: Gross margin improved to 50.1% from 44.5%. The prior year included $5.6 million in inventory write-offs related to product recalls. Excluding these charges, the 2001 margin was 57.0%. The 2002 margin was impacted by high unit costs of inventory manufactured during low-volume periods in 2001.
- Expense Reduction: Marketing and selling expenses decreased by $3.2 million (16%) due to cost containment and the closure of subsidiaries in Canada and South Africa.
- Non-Recurring Charges: The company recorded $1.5 million in "Other charges" related to foreign currency translation losses on closed subsidiaries and employee severance. Additionally, a $9.2 million non-cash valuation allowance was recorded against deferred tax assets, fully reserving them due to a history of cumulative losses.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Strategic Focus: Management aims to establish the custom-made ICL and Toric ICL as dominant revenue generators over the next 4-5 years. The company expects U.S. IOL sales to increase in 2003 due to tighter sales force management and improved delivery systems.
- Regulatory Milestones: The company anticipates filing a pre-market approval application for the ICL (myopia) with the FDA in the second quarter of 2003.
- Cost Efficiency: Gross profit margins are expected to improve sequentially as high-cost inventory is depleted.
Risks and Contingencies:
- Liquidity and Debt Covenants: The company has a history of losses and an accumulated deficit of $41.4 million. As of January 3, 2003, the company was not in compliance with tangible net worth covenants on its domestic credit facility, though a waiver was obtained. The credit line was extended to March 31, 2004, with reduced covenants.
- Product Recalls: The company faces risks associated with product recalls, which have historically caused significant inventory write-offs and revenue declines.
- Competition: Intense competition exists from larger firms (e.g., Alcon, Bausch & Lomb) with greater resources. The company relies on proprietary technology (Collamer material) and patents that may expire or be challenged.
- Regulatory Approval: Future growth depends heavily on FDA and international approvals for the ICL and other new products.
Investor Verification Checklist
- Debt Covenant Compliance: Verify the status of the waiver for tangible net worth covenants and the terms of the extended credit facility maturing March 31, 2004.
- ICL Regulatory Status: Monitor the timeline and outcome of the FDA pre-market approval application for the Implantable Contact Lens (ICL), expected in Q2 2003.
- Inventory Valuation: Assess the remaining high-cost inventory levels and the trajectory of gross margin improvement as this inventory is sold.
- Legal Settlements: Review the financial impact of recent settlements with former executives (John R. Wolf, Richard Leza) and the resolution of the shareholder derivative suit.
- Deferred Tax Assets: Evaluate the likelihood of reversing the $18.2 million valuation allowance on deferred tax assets, which would require a sustained history of profitability.